(Q42678980)

4 November 2017

title

Pharmacokinetics of the combination of fluvastatin and gemfibrozil (English)

1 reference

4 November 2017

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7604806

9 June 2024

author name string

J. D. Spence

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7604806

9 June 2024

C. E. Munoz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7604806

9 June 2024

L. Hendricks

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7604806

9 June 2024

L. Latchinian

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7604806

9 June 2024

H. E. Khouri

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7604806

9 June 2024

language of work or name

English

0 references

publication date

1 July 1995

1 reference

4 November 2017

13 July 1995

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7604806

full work available at URL

9 June 2024

https://api.elsevier.com/content/article/PII:S0002914905800244?httpAccept=text/xml

1 reference

10.1016/S0002-9149(05)80024-4

DOI

https://api.crossref.org/works/10.1016/S0002-9149(05)80024-4

https://api.elsevier.com/content/article/PII:S0002914905800244?httpAccept=text/plain

9 June 2024

1 reference

10.1016/S0002-9149(05)80024-4

DOI

https://api.crossref.org/works/10.1016/S0002-9149(05)80024-4

American Journal of Cardiology

9 June 2024

published in

1 reference

4 November 2017

volume

76

1 reference

4 November 2017

issue

2

1 reference

4 November 2017

page(s)

80A-83A

1 reference

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Clinical implications of new drugs for lowering plasma cholesterol concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Lovastatin and other HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Efficacy and long-term adverse effect pattern of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Combination drug therapy for familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Effects of combined bezafibrate-simvastatin appraised in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

High-dose fluvastatin and bezafibratecombination treatment for heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

Efficacy and safety of triple therapy(fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2805%2980024-4

10.1016/S0002-9149(05)80024-4

7 January 2021

Identifiers

DOI

1 reference

4 November 2017

1 reference